Effect of thalidomide combined with infliximab in treatment of refractory inflammatory bowel disease and its effects on insulin-like growth factor-1 and transforming growth factor-p1
- VernacularTitle:沙利度胺联合英夫利西治疗难治性炎症性肠病效果及对胰岛素样生长因子-1、转化生长因子-β1的影响
- Author:
Lijun MENG
1
;
Xiaohe GUO
;
Daiyuan DONG
;
Yan YANG
;
Yaofeng XUE
;
Baolin ZHOU
;
Yongmei QIN
Author Information
- Keywords: thalidomide; infliximab; refractory inflammatory bowel disease; insulin-like growth factor-1; transforming growth factor-β1; nutritional status
- From: Journal of Clinical Medicine in Practice 2024;28(1):68-72,77
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the effect of thalidomide combined with infliximab(IFX)in treatment of refractory inflammatory bowel disease(IBD)and its effects on insulin-like growth fac-tor-1(IGF-1)and transforming growth factor-β1(TGF-β1).Methods A total of 120 patients with refractory IBD were randomly divided into experimental group and control group,with 60 cases in each group.The two groups were given conventional treatment(mesalazine),the control group was given IFX,and the experimental group was given IFX combined with thalidomide,continuous treat-ment for two months.The efficacy,intestinal flora disturbance rate,adverse reactions,Crohn's dis-ease activity index(CDAI),Lewis score,serum IGF-1,TGF-β1 levels and nutritional status indexes[albumin(ALB),transferrin(Tf)]before and after treatment for 1 month and 2 months of the two groups were compared.Results The total effective rate of the experimental group was significantly higher than that of the control group(P＜0.05).After one month and two months of treatment,CDAI and Lewis scores of the experimental group were significantly lower than those of the control group(P＜0.05);the serum levels of IGF-1,TGF-β1 as well as ALB and Tf in the experimental group were significantly higher than those in the control group(P＜0.05).The improvement of intestinal flora disturbance rate in the experimental group was significantly better than that in the control group(P＜0.05).There was no significant difference in the incidence of oral and nasal mucosa dryness,throat discomfort,nausea and vomiting between two groups(P＞0.05).Conclusion In the treat-ment of refractory IBD patients,thalidomide combined with IFX can regulate serum IGF-1 and TGF-β1 levels,effectively relieve clinical manifestations,inhibit inflammatory activities,and improve nutri-tional status and intestinal flora disorders of patients,and it has high safety.
